# Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients

> **NCT00828503** · PHASE2 · UNKNOWN · sponsor: **Marcus Saemann** · enrollment: 40 (estimated)

## Conditions studied

- Cytomegalovirus Disease

## Interventions

- **DRUG:** Certican (everolimus) + valganciclovir
- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT00828503
- **Lead sponsor:** Marcus Saemann
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-12
- **Primary completion:** 2013-12
- **Final completion:** 2014-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828503, "Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00828503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*